Endocrinology, Vol 103, 1742-1751, Copyright © 1978 by Endocrine Society

ARTICLES

Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen

KB Horwitz, Y Koseki and WL McGuire

Estrogen antagonists are widely used in the treatment of breast cancer, and studies of their mechanism of action may provide clues to an understanding of tumor growth regulation and mechanisms of normal estrogen action. We have used human breast cancer cells in long term culture as an in vitro model to study the roles of estradiol and the antiestrogens, tamoxifen and nafoxidine, on cell growth and progesterone receptor (PgR) induction. Tamoxifen is found to have dual dose-dependent estrogenic/antiestrogenic properties. With 1 micrometer tamoxifen, cell growth and PgR induction are suppressed. These effects are reversed by estradiol. At lower doses (less than 0.1 micrometer), however, tamoxifen is a potent estrogen and rapidly induces (24--48 h) PgR, which increases 4- to 10-fold after 4--6 days and falls if tamoxifen is removed. Induction of PgR by estradiol is weaker but follows a similar time course. Tamoxifen-induced PgR is similar to that induced by estradiol; it sediments at 8S on sucrose density gradients, is a tight binder (R5020 Kd, 1.7 micrometer at 4 C and 0.87 nM at 15 C), and can be translocated to the nucleus by R5020. The dual properties of tamoxifen are not due to metabolic formation of an active antiestrogen from a prohormone precursor. In contrast, the action of the antiestrogen nafoxidine is not biphasic in MCF-7 cells; it does not induce PgR over a wide dose range and at high doses, the compound inhibits cell growth.

This article has been cited by other articles:

				J. C. Harrell, W. W. Dye, D. M.E. Harvell, M. Pinto, P. Jedlicka, C. A. Sartorius, and K. B. Horwitz Estrogen Insensitivity in a Model of Estrogen Receptor Positive Breast Cancer Lymph Node Metastasis Cancer Res., November 1, 2007; 67(21): 10582 - 10591. [Abstract] [Full Text] [PDF]

				L. C Murphy and P. H Watson Is oestrogen receptor- {beta} a predictor of endocrine therapy responsiveness in human breast cancer? Endocr. Relat. Cancer, June 1, 2006; 13(2): 327 - 334. [Abstract] [Full Text] [PDF]

				Y. Lin, J. Kokontis, F. Tang, B. Godfrey, S. Liao, A. Lin, Y. Chen, and J. Xiang Androgen and its receptor promote bax-mediated apoptosis. Mol. Cell. Biol., March 1, 2006; 26(5): 1908 - 1916. [Abstract] [Full Text] [PDF]

				G. Arpino, H. Weiss, A. V. Lee, R. Schiff, S. De Placido, C. K. Osborne, and R. M. Elledge Estrogen Receptor-Positive, Progesterone Receptor-Negative Breast Cancer: Association With Growth Factor Receptor Expression and Tamoxifen Resistance J Natl Cancer Inst, September 7, 2005; 97(17): 1254 - 1261. [Abstract] [Full Text] [PDF]

				B. M. Jacobsen, S. A. Schittone, J. K. Richer, and K. B. Horwitz Progesterone-Independent Effects of Human Progesterone Receptors (PRs) in Estrogen Receptor-Positive Breast Cancer: PR Isoform-Specific Gene Regulation and Tumor Biology Mol. Endocrinol., March 1, 2005; 19(3): 574 - 587. [Abstract] [Full Text] [PDF]

				R. C. Hovey, M. Asai-Sato, A. Warri, B. Terry-Koroma, N. Colyn, E. Ginsburg, and B. K. Vonderhaar Effects of Neonatal Exposure to Diethylstilbestrol, Tamoxifen, and Toremifene on the BALB/c Mouse Mammary Gland Biol Reprod, February 1, 2005; 72(2): 423 - 435. [Abstract] [Full Text] [PDF]

				J. P. Alao, E. W-F. Lam, S. Ali, L. Buluwela, W. Bordogna, P. Lockey, R. Varshochi, A. V. Stavropoulou, R. C. Coombes, and D. M. Vigushin Histone Deacetylase Inhibitor Trichostatin A Represses Estrogen Receptor {alpha}-Dependent Transcription and Promotes Proteasomal Degradation of Cyclin D1 in Human Breast Carcinoma Cell Lines Clin. Cancer Res., December 1, 2004; 10(23): 8094 - 8104. [Abstract] [Full Text] [PDF]

				J. Lu, A. Pierron, and K. Ravid An Adenosine Analogue, IB-MECA, Down-Regulates Estrogen Receptor {alpha} and Suppresses Human Breast Cancer Cell Proliferation Cancer Res., October 1, 2003; 63(19): 6413 - 6423. [Abstract] [Full Text] [PDF]

				M. Dowsett, N. J. Bundred, A. Decensi, R. C. Sainsbury, Y. Lu, M. J. Hills, F. J. Cohen, P. Veronesi, M. E. R. O'Brien, T. Scott, et al. Effect of Raloxifene on Breast Cancer Cell Ki67 and Apoptosis: A Double-Blind, Placebo-controlled, Randomized Clinical Trial in Postmenopausal Patients Cancer Epidemiol. Biomarkers Prev., September 1, 2001; 10(9): 961 - 966. [Abstract] [Full Text] [PDF]

				J. F. Robertson, R. I. Nicholson, N. J. Bundred, E. Anderson, Z. Rayter, M. Dowsett, J. N. Fox, J. M. W. Gee, A. Webster, A. E. Wakeling, et al. Comparison of the Short-Term Biological Effects of 7{alpha}-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17{beta}-diol (Faslodex) versus Tamoxifen in Postmenopausal Women with Primary Breast Cancer Cancer Res., September 1, 2001; 61(18): 6739 - 6746. [Abstract] [Full Text] [PDF]

				M. Dowsett, J. M. Dixon, K. Horgan, J. Salter, M. Hills, and E. Harvey Antiproliferative Effects of Idoxifene in a Placebo-controlled Trial in Primary Human Breast Cancer Clin. Cancer Res., June 1, 2000; 6(6): 2260 - 2267. [Abstract] [Full Text]

				K.-M. Lau, S. C. Mok, and S.-M. Ho Expression of human estrogen receptor-alpha and -beta , progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells PNAS, May 11, 1999; 96(10): 5722 - 5727. [Abstract] [Full Text] [PDF]

				T.-Y. Chun, D. Gregg, D. K. Sarkar, and J. Gorski Differential regulation by estrogens of growth and prolactin synthesis in pituitary cells suggests that only a small pool of estrogen receptors is required for growth PNAS, March 3, 1998; 95(5): 2325 - 2330. [Abstract] [Full Text] [PDF]

				N. Guthrie, A. Gapor, A. F. Chambers, and K. K. Carroll Inhibition of Proliferation of Estrogen Receptor-Negative MDA-MB-435 and -Positive MCF-7 Human Breast Cancer Cells by Palm Oil Tocotrienols and Tamoxifen, Alone and in Combination J. Nutr., March 1, 1997; 127(3): 544 - 544. [Abstract] [Full Text]

				U. Gundimeda, Z.-H. Chen, and R. Gopalakrishna Tamoxifen Modulates Protein Kinase C via Oxidative Stress in Estrogen Receptor-negative Breast Cancer Cells J. Biol. Chem., June 7, 1996; 271(23): 13504 - 13514. [Abstract] [Full Text] [PDF]

				J. H Kearsley Some basic guidelines in the use of chemotherapy for patients with incurable malignancy Palliative Medicine, January 1, 1994; 8(1): 11 - 17. [Abstract] [PDF]

				S. Shafie Estrogen and the growth of breast cancer: new evidence suggests indirect action Science, August 8, 1980; 209(4457): 701 - 702. [Abstract] [PDF]